JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects

Inclusion Criteria: 1. Age of 18-65 years (inclusive) ,women or man 2. SARS-CoV-2 detected in the diagnostic specimen (nasopharyngeal swab) 3. High homology of viral gene sequencing with the known SARS-CoV-2." 4. Mild/moderateillness COVID-19 or SARS-CoV-2 asymptomatic infection 5. Within 7 days from the onset time of symptoms to randomization or within 5 days from the first time of SARS-CoV-2 positive test to randomization with required viral load 6. No plan of pregnancy and being willing to use effective contraceptive measures 7. Signed the informed consent form, sufficiently understanding of the content Exclusion Criteria: 1. positive IgM/IgG against SARS-CoV-2 prior to randomization. 2. Severeor critical illness 3. Uncontrolled hypertension, cardiovascular/cerebrovascular diseases,lung diseases 4. Type 1 diabetes, or newly diagnosed or poorly controlled type 2 diabetes 5. Liver and kidney dysfunction, immune or inflammatory diseases, infections, surgery, tumors, and other major diseases 6. History of SARS-CoV-2 vaccination or participation in clinical trial with neutralizing antibody against SARS-CoV-2. 7. Use of therapeutic biologics within 3 months prior to screening, or within the elimination period (5 half-lives) of such drugs as the day of dosing 8. Has participated in any other interventional clinical study involving anstudy drug within 3 months prior to screening, or within the elimination period (5 half-lives) of the study drug as the day of dosing 9. Platelets and hemoglobin test results during screening period are abnormal and have clinical significanc. 10. Anaphylaxis, urine drug screening, alcohol dependence, lactation during pregnancy, blood loss, and others